Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin R Flaherty

Showing results (171-180 of 204) with videos related to

Pageof 21
Sort By:
American Journal of Respiratory and Critical Care Medicine|October 17, 2023
Proteomic Biomarkers of Survival in Idiopathic Pulmonary FibrosisJustin M Oldham, Yong Huang, Swaraj Bose, et al.
Scientific Reports|October 17, 2019
Low Dose Carbon Monoxide Exposure in Idiopathic Pulmonary Fibrosis Produces a CO Signature Comprised of Oxidative Phosphorylation GenesNancy Casanova, Tong Zhou, Manuel L Gonzalez-Garay, et al.
American Journal of Respiratory and Critical Care Medicine|February 22, 2019
Lung Microbiota Contribute to Pulmonary Inflammation and Disease Progression in Pulmonary FibrosisDavid N O'Dwyer, Shanna L Ashley, Stephen J Gurczynski, et al.
American Journal of Respiratory and Critical Care Medicine|February 4, 2017
Microbes Are Associated with Host Innate Immune Response in Idiopathic Pulmonary FibrosisYong Huang, Shwu-Fan Ma, Milena S Espindola, et al.
Science Translational Medicine|November 12, 2010
TLR9 differentiates rapidly from slowly progressing forms of idiopathic pulmonary fibrosisGlenda Trujillo, Alessia Meneghin, Kevin R Flaherty, et al.
Therapeutic Advances in Respiratory Disease|November 8, 2024
Bexotegrast in people with idiopathic pulmonary fibrosis (IPF): a plain language summary of publication of the INTEGRIS-IPF studyLisa Lancaster, Vincent Cottin, Murali Ramaswamy, et al.
American Journal of Respiratory and Critical Care Medicine|June 6, 2024
Biological Age, Chronological Age, and Survival in Pulmonary Fibrosis: A Causal Mediation AnalysisJanelle Vu Pugashetti, John S Kim, Swaraj Bose, et al.
The New England Journal of Medicine|May 20, 2014
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosisLuca Richeldi, Roland M du Bois, Ganesh Raghu, et al.
Annals of Internal Medicine|May 8, 2013
Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trialGanesh Raghu, Juergen Behr, Kevin K Brown, et al.
The European Respiratory Journal|July 27, 2014
Smoking-related idiopathic interstitial pneumoniaKevin R Flaherty, Charlene Fell, Marie-Christine Aubry, et al.
Pageof 21

Showing results (171-180 of 204) with videos related to

Sort By:
Pageof 21
American Journal of Respiratory and Critical Care Medicine|October 17, 2023
Proteomic Biomarkers of Survival in Idiopathic Pulmonary FibrosisJustin M Oldham, Yong Huang, Swaraj Bose, et al.
Scientific Reports|October 17, 2019
Low Dose Carbon Monoxide Exposure in Idiopathic Pulmonary Fibrosis Produces a CO Signature Comprised of Oxidative Phosphorylation GenesNancy Casanova, Tong Zhou, Manuel L Gonzalez-Garay, et al.
American Journal of Respiratory and Critical Care Medicine|February 22, 2019
Lung Microbiota Contribute to Pulmonary Inflammation and Disease Progression in Pulmonary FibrosisDavid N O'Dwyer, Shanna L Ashley, Stephen J Gurczynski, et al.
American Journal of Respiratory and Critical Care Medicine|February 4, 2017
Microbes Are Associated with Host Innate Immune Response in Idiopathic Pulmonary FibrosisYong Huang, Shwu-Fan Ma, Milena S Espindola, et al.
Science Translational Medicine|November 12, 2010
TLR9 differentiates rapidly from slowly progressing forms of idiopathic pulmonary fibrosisGlenda Trujillo, Alessia Meneghin, Kevin R Flaherty, et al.
Therapeutic Advances in Respiratory Disease|November 8, 2024
Bexotegrast in people with idiopathic pulmonary fibrosis (IPF): a plain language summary of publication of the INTEGRIS-IPF studyLisa Lancaster, Vincent Cottin, Murali Ramaswamy, et al.
American Journal of Respiratory and Critical Care Medicine|June 6, 2024
Biological Age, Chronological Age, and Survival in Pulmonary Fibrosis: A Causal Mediation AnalysisJanelle Vu Pugashetti, John S Kim, Swaraj Bose, et al.
The New England Journal of Medicine|May 20, 2014
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosisLuca Richeldi, Roland M du Bois, Ganesh Raghu, et al.
Annals of Internal Medicine|May 8, 2013
Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trialGanesh Raghu, Juergen Behr, Kevin K Brown, et al.
The European Respiratory Journal|July 27, 2014
Smoking-related idiopathic interstitial pneumoniaKevin R Flaherty, Charlene Fell, Marie-Christine Aubry, et al.
Pageof 21